Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

The latest update is out from Pharming Group ( (PHAR) ).

On June 11, 2025, Pharming Group N.V. announced the approval of all proposals at its Annual General Meeting of Shareholders. Notably, Dr. Elaine Sullivan was appointed to the Board of Directors, while Mrs. Jabine van der Meijs and Mr. Leonard Kruimer were re-elected as Non-Executive Directors. The meeting also saw the reappointment of Deloitte Accountants B.V. as the external auditor and the renewal of authorizations for the Board to issue and repurchase shares. The departures of Mrs. Deborah Jorn and Mr. Steven Baert from the Board were acknowledged with gratitude for their contributions.

The most recent analyst rating on (PHAR) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.

Spark’s Take on PHAR Stock

According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.

Pharming Group’s overall stock score reflects a strong earnings call with significant revenue growth, offset by poor valuation and mixed financial performance. Technical analysis indicates bullish momentum, but negative profitability remains a concern. Strategic initiatives and guidance upgrades provide optimism for future growth.

To see Spark’s full report on PHAR stock, click here.

More about Pharming Group

Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is involved in the commercialization and development of innovative medicines, including small molecules and biologics, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific.

Average Trading Volume: 4,622

Technical Sentiment Signal: Buy

Current Market Cap: $805.6M

For an in-depth examination of PHAR stock, go to TipRanks’ Stock Analysis page.